Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (CSE: $FONE.C) (TSXV: $VGW.V), (CSE: $OILS.C), (TSX: $WEED.TO) (NYSE: $CGC), (CSE: $TER.C)
Delta, Kelowna, BC –September 16, 2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Today's podcast overview/transcript
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts
In today’s podcast we look at a few early announcements.
Flower One Holdings Inc. (CSE: FONE) (OTCQX: FLOOF), announced the official, operational launch of its technologically advanced cannabis production lab which will operate alongside the Company's 400,000 square-foot greenhouse.
The new production space encompasses approximately 55,000 square feet and can readily consume between 3,000 – 5,000 pounds of biomass per week – with distillate processing from its ethanol extraction train in the 100-150 liter per week range. Today's announcement enhances Flower One's ability to generate product from its more than 140,000 pounds (62,500 kg) of dry cannabis flower and trim expected annually from the greenhouse.
Thomas Rosengren, Director of Extraction & Production reported: "The Launch of Flower One's bulk distillate process train has been a resounding success – with early lot potencies already testing in the 90%+ range."
Flower One's production lab has been intentionally designed for large-scale product fulfillment. By leveraging multiple extraction methods – namely ethanol, LPG, and CO2 – that run in parallel, Flower One has access to three upstream extraction channels, granting it the flexibility to leverage the specific extraction techniques needed to produce a wide range of cannabis products. Beyond extraction, the lab will engage in refinement, compounding, and commercial-kitchen-related activities, including ongoing optimization via data-driven continuous improvement processes.
"The product and test results coming out of the lab mark another huge milestone for Flower One and our ability to produce premium quality cannabis products" said Kellen O'Keefe, Chief Strategy Officer at Flower One. "Flower One is thrilled to bring some of the nation's leading cannabis brands to Nevada's retailers and consumers," he added.
Valens GroWorks Corp. (TSXV: VGW) (OTC: VGWCF) announced that it has entered into an agreement to supply cannabis oil derivative products to Medical Cannabis by Shoppers, the online medical cannabis ecommerce site of one of Canada's most trusted pharmacy retailers.
Valens will utilize their five different types of extraction services including CO2, Ethanol, Hydrocarbon, Solvent-less, and Terpene extraction as well as its IP and formulation services to create a variety of innovate oil-based products for Shoppers' medical platform. Under the agreement, Valens will immediately begin production of gel caps and tinctures with further expansion of product offerings to include vaporizer cartridges, topicals and other desired products as permitted for sale by Health Canada regulations.
"Valens is proud to be chosen as the first third party extraction and product development company to supply cannabis oil products to one of the most recognized pharmacy retailers in Canada." said Tyler Robson, CEO of Valens. "Shoppers Drug Mart is a highly respected, trusted brand that consistently delivers premium products that patients can trust. Our industry leading extraction, analytical testing and product formulation capabilities are ideally positioned to deliver the high quality, oil-based products and services expected from such a reputable industry leader such as Shoppers. This new partnership will advance our product development portfolio as we continue to enhance our capabilities and increase our market presence."
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) announced entering into an exclusive supply agreement with BevCanna Enterprises Inc., an emerging leader in cannabis infused beverages, based in BC, Canada.
Nextleaf has granted exclusive license to BevCanna for the use of intellectual property related to water-soluble cannabinoids for the development, manufacturing and sale of BevCanna products. This will include BevCanna's portfolio of house brands, and white label products developed by BevCanna for third parties.
Performance milestones include commercialization within 12 months of the legalization of infused products and edibles in Canada. The initial term of the agreement extends for 3 years after the legalization of infused products, and subsequent 5-year renewal period.
"BevCanna has a world-class bottling plant on a spring water aquifer, its one of the most unique licensed production facilities in Canada," said Paul Pedersen, Nextleaf CEO. "The BevCanna team brings a tremendous amount of experience in creating iconic beverage brands and consumer packaged goods, such as Mike's Hard Lemonade, Vega, and Trace Beverages. BevCanna is a great example of the caliber of partner we want to commercialize our IP through." stated Pedersen.
BevCanna has recently shared two of its intended brands for commercialization in Canada, including Anarchist Mountain Beverages, a line of THC infused sparkling spring water beverages with botanical flavor profiles inspired by the Pacific Northwest. Additionally, Gruv, a line of easy-drinking iced tea beverages, with a blend of THC and CBD.
"We are very pleased to leverage Nextleaf's technology within our formulations, as they have a proven reputation for unique and differentiated IP," shared Emma Andrews, Chief Commercialization Officer at BevCanna. "Their patented extraction and purification process will allow our beverages to be made with odorless, tasteless cannabinoids, resulting in a superior taste and consumption experience. A natural compliment to our premium spring water base. We believe taste and reliability will be essential to growing this category." Andrews said.
Through the Standard Processing License announced last week for Nextleaf Labs, and under BevCanna's recently issued Research License, product development activities will take a significant step forwards, including stability validation, sensory evaluation, and equipment testing, in preparation for scale-up towards full commercialization.
Santé Cannabis, a pioneer in medical cannabis in Québec, has partnered with Spectrum Therapeutics, the medical division of Canopy Growth (TSX: WEED) (NYSE: CGC) to launch the Prescriber Training Program, designed to aid physicians and patients, announced today at the new Santé Cannabis clinic and research centre in Montréal.
This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. The program will be offered for free to Québec physicians and is made possible by an unrestricted educational grant from Spectrum Therapeutics.
"Patient referrals and training requests from our physician colleagues have increased by more than 500 per cent over the last year," says Dr. Michael Dworkind, Medical Director of Santé Cannabis and McGill University Associate Professor of Family Medicine. "It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool. In this program, we extend our experience and expertise to healthcare professionals, in order to support them to meet the needs of their patients."
The Prescriber Training Program is designed by clinicians for clinicians, and gives a unique, practical approach to medical cannabis learning. It provides participating physicians with:
● Self-learning modules that detail treatment evidence for specific conditions and symptoms;
● Ongoing personalized phone support for questions about medical cannabis and patient care;
● Clinical preceptorship opportunities at four Santé Cannabis locations across Québec;
● Practical reference guidebook on developing and managing treatment plans and dosing; and
● Clinical toolkits to help navigate patient assessment and follow-ups.
"A significant issue preventing the consideration of cannabinoid medicine by healthcare professionals is that the topic is not typically included in the medical school curriculum," comments Dr. Mark Ware, Chief Medical Officer, Canopy Growth. "We've invested in a range of training and education initiatives to address this gap in knowledge, and this new program creates an important resource for Québec physicians interested in learning how to integrate medical cannabis into their practice."
As Québec's first and foremost medical cannabis clinic and research centre, Santé Cannabis has received referrals from more than 2,500 physicians and assessed over 6,000 patients since 2014, while also providing information sessions for patients and healthcare professionals. Spectrum Therapeutics' track record with providing industry-leading education, resources and support for healthcare professionals includes:
● Evidence-based educational courses in Canada that have been delivered to thousands of physicians, nurses, and pharmacists, including accredited medical education programs through the Canadian Council on Continuing Education in Pharmacy (CCCEP)
● A first-of-its-kind Catalyst Peer Mentorship Program, which links physicians from across Canada with colleagues who possess advanced knowledge of the cannabis field in order to provide case-by-case support.
● 71,000+ interactions with healthcare professionals
Today, Syqe Medical, Ltd. and TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) announced an exclusive distribution agreement to bring Syqe's flagship product, the Syqe™ Inhaler, to the Canadian market. Backed by rigorous clinical trials, the Syqe Inhaler is the world's first metered-dose medical cannabis inhaler to provide predictable, precise and consistent treatment at pharmaceutical standards. Syqe first debuted its product to the Israeli market in June 2019, and through TerrAscend is bringing its breakthrough technology to the Canadian market to ease the suffering of patients dealing with chronic conditions.
"Syqe's goal since inception has been to bring relief to as many patients as possible in the fastest possible way, and we spent eight years developing the Syqe Inhaler to ensure that when introduced, it would make a significant positive impact on patients' lives," says Perry Davidson, Syqe CEO and Founder. "We have been searching for a partner that is truly focused on the medical side of cannabis. We are thrilled to be working with TerrAscend to share our groundbreaking technology with a progressive market at the forefront of medical cannabis treatment."
TerrAscend, through its wholly owned subsidiaries TerrAscend Canada and Solace Health Network, will lead marketing, distribution and sales efforts across Canada. Through Solace Health's patient-centric online platform and medical coverage assistance, as well as its wide network of medical professionals, TerrAscend is uniquely positioned for success with the Syqe treatment in the Canadian medical cannabis market.
As part of the agreement, TerrAscend will utilize their platform to both provide high quality guidance to patients on use of the Syqe device and educate the medical community on the benefits of medical cannabis and the Syqe treatment.
"We've seen time and again the deficiencies of current drug delivery devices – whether it be dosage inconsistencies or side effects – and recognize that the industry is ready to be disrupted," says Michael Nashat, TerrAscend's CEO. "Syqe's device is on the cutting edge of drug delivery technology, and we are excited to facilitate their entry into the Canadian medical cannabis market, as there is a real need for a new approach to an age-old problem."
Syqe's entrance into the Canadian market comes at an opportune time, with patient treatment primed for improvement. A 2018 Health Canada survey shows that 71% of Canadians using medical cannabis consume it in dried flower or leaf form. The Syqe inhaler provides an effective alternative that ensures precise dosing for cannabis delivered by inhalation, while eliminating the hazards of smoking.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info:
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
